Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > January 2014 - Volume 22 - Issue 1 > Use of Intravenous Minocycline for the Treatment of Methicil...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e31828bbb82
Original Articles

Use of Intravenous Minocycline for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Resistant Gram-Negative Organisms: Experience in a Tertiary Care Hospital

Bishburg, Eliahu MD*; Shah, Monica PharmD; Chan, Trini MS

Collapse Box

Abstract

Background

Minocycline (MINO), a tetracycline antibiotic, has been available since the 1960s. The intravenous (IV) formulation was withdrawn from the market in 2005 but was reintroduced in the US market in 2009. The drug has potent activity against methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant gram-negative organisms (MDRO), specifically Acinetobacter baumannii, extended-spectrum β-lactamase (ESBL), and Klebsiella pneumoniae carbapenemase-producing Klebsiella and Escherichia coli species. We used IV MINO in various clinical situations, where there were few or no other options for treatment.

Methods

All cases treated with IV MINO from 2009 to 2012 were reviewed. Data were collected for demographics, reasons for IV MINO use, and outcome.

Results

Twenty-one patients were treated with IV MINO; 12 patients had MRSA infections, 3 patients had mixed MRSA and gram-negative infections, and 8 patients had MDRO infections. There were 8 patients with bacteremia, 5 patients with pneumonia, 8 patients with skin and soft tissue infections, one patient each with endocarditis and osteomyelitis, and 2 patients had urinary tract infection. Twelve patients continued treatment with oral MINO. Twenty patients were discharged, and one patient died.

Conclusions

Intravenous MINO is an excellent treatment option for certain MRSA and MDRO infections, where there is a paucity of treatment options. The drug has a favorable pharmacokinetic profile and allows for completion of treatment with an oral formulation.

Copyright © 2013 by Lippincott Williams & Wilkins

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.